Hcv treat now or defer
This presentation is the property of its rightful owner.
Sponsored Links
1 / 13

HCV: Treat now or Defer PowerPoint PPT Presentation


  • 64 Views
  • Uploaded on
  • Presentation posted in: General

HCV: Treat now or Defer. Todd Wills, MD ETAC Infectious Disease Specialist. Excerpted and adapted from: Seizing the Opportunity: Optimizing Today’s HCV Therapies, Exploring Their Role in Tomorrow’s Paradigm – Clinical Care Options - Hepatitis. HEPATITIS C TREATMENT EXPANSION INITIATIVE

Download Presentation

HCV: Treat now or Defer

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Hcv treat now or defer

HCV: Treat now or Defer

Todd Wills, MD

ETAC Infectious Disease Specialist

Excerpted and adapted from: Seizing the Opportunity: Optimizing Today’s HCV Therapies, Exploring Their Role in Tomorrow’s Paradigm – Clinical Care Options - Hepatitis

HEPATITIS C TREATMENT EXPANSION INITIATIVE

MULTISITE CONFERENCE CALL

JUNE 19, 2013


Why treat chronic hepatitis c

Why Treat Chronic Hepatitis C?

1. Kanwal F, et al. Gastroenterology. 2011;140:1182-1188. 2. Shaw JJ, et al. Expert Rev Gastroenterol Hepatol. 2011;5:365-370. 3. Poynard T, et al. Gastroenterology. 2002;122:1303-1313. 4. Craxi A, et al. Clin Liver Dis. 2005;9:329-346. 5. Shiratori Y, et al. Ann Intern Med. 2005;142:105-114.

  • The disease

    • Common, chronic, and potentially progressive

    • Complications are becoming more common[1,2]

      • Liver failure, HCC

  • The treatment

    • Viral cure, or SVR, is achievable

    • SVR associated with histologic improvement and gradual regression of fibrosis[3]

    • SVR reduces risk for liver failure and HCC, improves survival[4,5]


We understand the rules of the game with ifn based treatment

We Understand the Rules of the Game With IFN-Based Treatment

Establishing patient candidacy

Assessing potential drug–drug interactions

Evaluating likelihood of SVR in treatment-naive and treatment-experienced patients

Applying response-guided treatment algorithms to maximize response and mitigate treatment failure

Optimally managing adverse events


For genotype 2 or 3 pegifn rbv remains standard of care

For Genotype 2 or 3, PegIFN/RBV Remains Standard of Care

  • Highly effective therapy with higher cure rates than genotype 1

  • 24 wks of therapy is recommended[1,2]

    • Some patients (with RVR and low baseline HCV RNA) may be treated for 16 wks if therapy poorly tolerated, although relapse rates may be higher[2]

  • Future regimens may offer further improvements

1. Ghany MG, et al. Hepatology. 2011;54:1433-1444. 2. EASL. J Hepatol. 2011;55:245-264.


Rationale for prompt treatment of hcv

Rationale for Prompt Treatment of HCV

  • HCV is a progressive disease, associated with persistence of viral replication and ongoing necroinflammation and fibrosis

  • Remission (SVR) is associated with loss of active viral replication and improvement in hepatic fibrosis

  • Important questions

    • Does that equate to a need to treat all patients?

    • Can we avoid losing time for patients destined to progress?

    • How do we avoid unnecessary or detrimental treatment when there are improved treatments pending?


Indications for treatment of chronic hcv infection

Indications for Treatment of Chronic HCV Infection

  • All patients, regardless of the degree of fibrosis, are potential candidates for treatment

  • Patients with mild disease may not require immediate treatment

  • For those who require treatment

    • Patients should be fit for the regimen

    • Patients should have the ability to adhere to treatment goals and monitoring


Who should be treated now

Who Should Be Treated Now?

Pts Who Are Motivated and Understand . . .

  • Likelihood of response

  • Risks/benefits of treatment

  • Risk of resistance

  • Possibility of shortened therapy

  • What is “coming down the line” for their genotype

Pts Who Want Tx

  • Want to be cured of disease

  • Personal or social reasons

  • Plans for pregnancy

  • Social support

  • Eligible for reimbursement now

Pts Who Are Eligible for Tx

  • Eligible for pegIFN/ RBV

  • Fit for regimen

  • No contraindications

  • Disease stage


Severity of disease increases need for hcv therapy but also impairs response

Severity of Disease Increases Need for HCV Therapy but Also Impairs Response

  • May not need immediate treatment

  • BUT

    • Easier to treat

    • High likelihood of response

  • Greater need for treatment

  • BUT

    • Response may be impaired

  • Perhaps more effective options in future, but efficacy of some investigational agents may be unclear due to trial eligibility criteria

Mild disease

Advanced disease/ cirrhosis


What are my chances of being cured with current therapy

What Are My Chances of Being Cured With Current Therapy?

  • Black

  • Cirrhosis

  • Genotype 1 (1a worse than 1b)

  • IFN nonresponsive

  • IL28B TT

  • White

  • No fibrosis

  • Genotype 2/3

  • IFN responsive (eg, RVR/EVR or response to lead-in)

  • Previous relapser

  • IL28B CC

Less favorable prognostic factors

Favorable prognostic factors


Limitations of current regimens and prospects for future regimens

Limitations of Current Regimens and Prospects for Future Regimens

Current

Must be eligible for pegIFN/ RBV

Large pill burden, TID dosing of PIs (at present); parenteral IFN

Challenging adverse events

High likelihood of resistance with treatment failure

Current PIs only effective for genotype 1

Possibility of resistance with poor adherence

Future

Perhaps IFN free

Lower pill burden, less than TID dosing; perhaps all oral

May be better tolerated

May not generate resistance

Pangenotypic or at least more

Higher barrier to resistance with some classes


Challenging patients for whom treatment with current options less than optimal

Challenging Patients for Whom Treatment With Current Options Less Than Optimal

  • Cirrhosis (all genotypes)

  • Decompensated cirrhosis

  • Null responders

  • Pretransplantation

  • Posttransplantation

  • Renal failure

    • Impaired renal function

    • Dialysis

    • Renal transplantation recipients

  • Injection-drug users

    • Methadone substitution

  • Thalassemics

  • Children

  • IFN contraindicated

  • IFN intolerant

  • Those on “edge” of society

  • Psychiatric comorbidity


The need to cure cirrhosis survival in patients with hcv and cirrhosis

The Need to Cure Cirrhosis: Survival in Patients With HCV and Cirrhosis

Survival Probability

Compensated

100

After first major complication

80

60

Patients (%)

40

20

0

0

12

24

36

48

60

72

84

96

108

120

Mos

38465

37639

34221

28811

2367

1654

1264

793

523

392

251

Pts at Risk, n

Fattovich G, et al. Gastroenterology. 1997;112:463-472.


The first generation protease inhibitors where are we now

The First-Generation Protease Inhibitors: Where Are We Now?

  • Telaprevir and boceprevir are harbingers of important treatment advance

  • Improved SVR rates in both naive and experienced patients

  • Certain patients (advanced disease) require therapy imminently and should be treated now

  • Others may be motivated to be treated now—opportunities for cure, candidates for shortened therapy, and/or personal reasons

  • For many, the choice is not clear

  • The advent of triple therapy changes the way treatment discussed with patients

    • Clinicians must educate and advocate for patients to choose the correct course of treatment


  • Login